Search

Your search keyword '"Valipour, Arschang"' showing total 507 results
Start Over Author "Valipour, Arschang"
507 results on '"Valipour, Arschang"'

3. Author Correction: In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer

Author

Dervovic, Dzana, Malik, Ahmad A., Chen, Edward L. Y., Narimatsu, Masahiro, Adler, Nina, Afiuni-Zadeh, Somaieh, Krenbek, Dagmar, Martinez, Sebastien, Tsai, Ricky, Boucher, Jonathan, Berman, Jacob M., Teng, Katie, Ayyaz, Arshad, Lü, YiQing, Mbamalu, Geraldine, Loganathan, Sampath K., Lee, Jongbok, Zhang, Li, Guidos, Cynthia, Wrana, Jeffrey, Valipour, Arschang, Roux, Philippe P., Reimand, Jüri, Jackson, Hartland W., and Schramek, Daniel

Published
2023
Full Text
View/download PDF

4. In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer

Author

Dervovic, Dzana, Malik, Ahmad A., Chen, Edward L. Y., Narimatsu, Masahiro, Adler, Nina, Afiuni-Zadeh, Somaieh, Krenbek, Dagmar, Martinez, Sebastien, Tsai, Ricky, Boucher, Jonathan, Berman, Jacob M., Teng, Katie, Ayyaz, Arshad, Lü, YiQing, Mbamalu, Geraldine, Loganathan, Sampath K., Lee, Jongbok, Zhang, Li, Guidos, Cynthia, Wrana, Jeffrey, Valipour, Arschang, Roux, Philippe P., Reimand, Jüri, Jackson, Hartland W., and Schramek, Daniel

Published
2023
Full Text
View/download PDF

7. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

Author

Illini, Oliver, primary, Saalfeld, Felix Carl, additional, Christopoulos, Petros, additional, Duruisseaux, Michaël, additional, Vikström, Anders, additional, Peled, Nir, additional, Demedts, Ingel, additional, Dudnik, Elizabeth, additional, Eisert, Anna, additional, Hashemi, Sayed M. S., additional, Janzic, Urska, additional, Kian, Waleed, additional, Mohorcic, Katja, additional, Mohammed, Saara, additional, Silvoniemi, Maria, additional, Rothschild, Sacha I., additional, Schulz, Christian, additional, Wesseler, Claas, additional, Addeo, Alfredo, additional, Armster, Karin, additional, Itchins, Malinda, additional, Ivanović, Marija, additional, Kauffmann-Guerrero, Diego, additional, Koivunen, Jussi, additional, Kuon, Jonas, additional, Pavlakis, Nick, additional, Piet, Berber, additional, Sebastian, Martin, additional, Velthaus-Rusik, Janna-Lisa, additional, Wannesson, Luciano, additional, Wiesweg, Marcel, additional, Wurm, Robert, additional, Albers-Leischner, Corinna, additional, Aust, Daniela E., additional, Janning, Melanie, additional, Fabikan, Hannah, additional, Herold, Sylvia, additional, Klimova, Anna, additional, Loges, Sonja, additional, Sharapova, Yana, additional, Schütz, Maret, additional, Weinlinger, Christoph, additional, Valipour, Arschang, additional, Overbeck, Tobias Raphael, additional, Griesinger, Frank, additional, Jakopovic, Marko, additional, Hochmair, Maximilian J., additional, and Wermke, Martin, additional

Published
2024
Full Text
View/download PDF

8. Shall We Screen Lung Cancer with Volume Computed Tomography in Austria? A Cost-Effectiveness Modelling Study.

Author

ten Berge, Hilde, Ramaker, Dianne, Piazza, Greta, Pan, Xuanqi, Lamprecht, Bernd, Valipour, Arschang, and Prosch, Helmut

Subjects
RISK assessment, QUALITY-adjusted life years, COST effectiveness, RESEARCH funding, EARLY detection of cancer, COMPUTED tomography, SMOKING, UNCERTAINTY, DESCRIPTIVE statistics, LONGITUDINAL method, LUNG tumors, COMPARATIVE studies, SENSITIVITY & specificity (Statistics), MEDICAL care costs, ECONOMICS, DISEASE risk factors
Abstract

Simple Summary: Lung cancer screening (LCS) aims to detect lung cancer in an early stage. Currently, the majority of lung cancer cases are detected in a late stage of the disease, while early detection of lung cancer is associated with better survival rates compared to late-stage disease detection. This study aimed to assess the cost-effectiveness of LCS compared to no screening program in Austria. LCS exhibited an incremental cost-effectiveness ratio (ICER) of EUR 24,627 per quality-adjusted life year (QALY), indicating that LCS is cost-effective. Moreover, the study demonstrated that LCS could avert 11,906 premature lung cancer deaths. These findings provide valuable insights crucial for evidence-based decision making regarding the prospective implementation of LCS initiatives in Austria. This study assessed the cost-effectiveness of a lung cancer screening (LCS) program using low-dose computed tomography (LDCT) in Austria. An existing decision tree with an integrated Markov model was used to analyze the cost-effectiveness of LCS versus no screening from a healthcare payer perspective over a lifetime horizon. A simulation was conducted to model annual LCS for an asymptomatic high-risk population cohort aged 50–74 with a smoking history using the Dutch–Belgian Lung Cancer Screening Study (NEderlands-Leuvens Longkanker ScreeningsONderzoek, NELSON) screening outcomes. The principal measure utilized to assess cost-effectiveness was the incremental cost-effectiveness ratio (ICER). Sensitivity and scenario analyses were employed to determine uncertainties surrounding the key model inputs. At an uptake rate of 50%, 300,277 eligible individuals would participate in the LCS program, yielding 56,122 incremental quality-adjusted life years (QALYs) and 84,049 life years gained compared to no screening, with an ICER of EUR 24,627 per QALY gained or EUR 16,444 per life-year saved. Additionally, LCS led to the detection of 25,893 additional early-stage lung cancers and averted 11,906 premature lung cancer deaths. It was estimated that LCS would incur EUR 945 million additional screening costs and EUR 386 million additional treatment costs. These estimates were robust in sensitivity analyses. Implementation of annual LCS with LDCT for a high-risk population, using the NELSON screening outcomes, is cost-effective in Austria, at a threshold of EUR 50,000 per QALY. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Author

Pison Christophe, L. Shah Pallav, Slebos Dirk-Jan, Ninane Vincent, Janssens Wim, Perez Thierry, Kessler Romain, Deslee Gaetan, L. Garner Justin, E. Hartman Jorine, Degano Bruno, Mayr Anna, Mayse Martin, D. Peterson Alexander, and Valipour Arschang

Subjects
COPD, Nerves, Targeted lung denervation, Acetylcholine, Anticholinergic, Bronchoscopy, Diseases of the respiratory system, RC705-779
Abstract

Abstract Background Targeted lung denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung reducing clinical consequences of cholinergic hyperactivity. The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe, symptomatic COPD. This analysis evaluated the long-term impact of TLD on COPD exacerbations, pulmonary function, and quality of life over 3 years of follow up. Methods TLD was performed in a prospective, energy-level randomized (29 W vs 32 W power), multicenter study (NCT02058459). Additional patients were enrolled in an open label confirmation phase to confirm improved gastrointestinal safety after procedural modifications. Durability of TLD was evaluated at 1, 2, and 3 years post-treatment and assessed through analysis of COPD exacerbations, pulmonary lung function, and quality of life. Results Three-year follow-up data were available for 73.9% of patients (n = 34). The annualized rate of moderate to severe COPD exacerbations remained stable over the duration of the study. Lung function (FEV1, FVC, RV, and TLC) and quality of life (SGRQ-C and CAT) remained stable over 3 years of follow-up. No new gastrointestinal adverse events and no unexpected serious adverse events were observed. Conclusion TLD in COPD patients demonstrated a positive safety profile out to 3 years, with no late-onset serious adverse events related to denervation therapy. Clinical stability in lung function, quality of life, and exacerbations were observed in TLD treated patients over 3 years of follow up.

Published
2021
Full Text
View/download PDF

13. Influence of Achalasia on the Spirometry Flow–Volume Curve and Peak Expiratory Flow.

Author

Jankovic, Jelena, Milenkovic, Branislava, Simic, Aleksandar, Skrobic, Ognjan, Valipour, Arschang, Ivanovic, Nenad, Buha, Ivana, Milin-Lazovic, Jelena, Djurdjevic, Natasa, Jandric, Aleksandar, Colic, Nikola, Stojkovic, Stefan, and Stjepanovic, Mihailo

Subjects
EXPIRATORY flow, ESOPHAGEAL motility disorders, ESOPHAGEAL achalasia, SPIROMETRY, ESOPHAGOGASTRIC junction
Abstract

Background: Achalasia is an esophageal motor disorder characterized by aperistalsis and the failure of the relaxation of the lower esophageal sphincter. We want to find out whether external compression or recurrent micro-aspiration of undigested food has a functional effect on the airway. Methods: The aim of this research was to analyze the influence of achalasia on the peak expiratory flow and flow–volume curve. All of the 110 patients performed spirometry. Results: The mean diameter of the esophagus was 5.4 ± 2.1 cm, and nine of the patients had mega-esophagus. Seven patients had a plateau in the inspiratory part of the flow–volume curve, which coincides with the patients who had mega-esophagus. The rest of the patients had a plateau in the expiration part of the curve. The existence of a plateau in the diameter of the esophagus of more than 5 cm was significant (p 0.003). Statistical significance between the existence of a plateau and a lowered PEF (PEF < 80) has been proven (p 0.001). Also, a statistical significance between the subtype and diameter of more than 4 cm has been proved. There was no significant improvement in the PEF values after operation. In total, 20.9% of patients had a spirometry abnormality finding. The frequency of the improvement in the spirometry values after surgery did not differ significantly by achalasia subtype. The improvement in FEV1 was statistically significant compared to the FVC values. Conclusions: Awareness of the influence of achalasia on the pulmonary parameters is important because low values of PEF with a plateau on the spirometry loop can lead to misdiagnosis. The recognition of various patterns of the spirometry loop may help in identifying airway obstruction caused by another non-pulmonary disease such as achalasia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD

Author

Koblizek, Vladimir, primary, Milenkovic, Branislava, additional, Svoboda, Michal, additional, Kocianova, Jana, additional, Holub, Stanislav, additional, Zindr, Vladimir, additional, Ilic, Miroslav, additional, Jankovic, Jelena, additional, Cupurdija, Vojislav, additional, Jarkovsky, Jiri, additional, Popov, Boris, additional, and Valipour, Arschang, additional

Published
2023
Full Text
View/download PDF

20. Bronchoscopic Thermal Vapor Ablation (BTVA) in patients with severe upper lobe predominant emphysema: 36 months follow-up results from a prospective registry

Author

Kontogianni, Konstantina, primary, Valipour, Arschang, additional, Eisenmann, Stephan, additional, Ficker, Joachim H., additional, Franzen, Daniel P., additional, Gesierich, Wolfgang, additional, Grah, Christian, additional, Hetzel, Martin, additional, Hammerl, Peter, additional, Herth, Felix J., additional, and Darwiche, Kaid, additional

Published
2023
Full Text
View/download PDF

23. Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types

Author

Robinson, Irina, primary, Hochmair, Maximilian Johannes, additional, Schmidinger, Manuela, additional, Absenger, Gudrun, additional, Pichler, Martin, additional, Nguyen, Van Anh, additional, Richtig, Erika, additional, Rainer, Barbara Margaretha, additional, Ay, Leyla, additional, Jansen, Christian, additional, Pacífico, Cátia, additional, Knabl, Alexander, additional, Sladek, Barbara, additional, Gasche, Nikolaus, additional, and Valipour, Arschang, additional

Published
2023
Full Text
View/download PDF

24. Transbronchial Cryobiopsy in the First 51 Patients: Diagnostic Yield, Complication Rates and Survival After 8 Years

Author

Gómez López, Antolina, primary, Valipour, Arschang, additional, de Miguel Poch, Eduardo, additional, García Luján, Ricardo, additional, del Pozo Rivas, Roberto, additional, Pérez Rojo, Raquel, additional, Enguita Vals, Ana Belén, additional, Alonso Charterina, Sergio, additional, de Granda Orive, Ignacio, additional, Álvarez Martínez, Carlos José, additional, Pérez González, Virginia, additional, Gámez García, Pablo, additional, Cortés Guerrero, Manuel, additional, and Villena Garrido, Victoria, additional

Published
2023
Full Text
View/download PDF

28. Computed tomographic airway morphology after targeted lung denervation treatment in COPD

Author

Hartman, Jorine E., primary, Herth, Felix J.F., additional, Shah, Pallav, additional, Pison, Christophe, additional, Valipour, Arschang, additional, Slebos, Dirk-Jan, additional, Abele, Christine, additional, Firlinger, Irene, additional, Kothakuzhakal, Kiran, additional, Duller, Marina, additional, Lamprecht, Bernd, additional, Kropfmueller, Roland, additional, Holzmann, Kornelia, additional, Rathmeier, Sandra, additional, Hubner, Ralf, additional, Erdmann, Leonore, additional, Temmesfeld-Wollbrück, Bettina, additional, Ruwwe Glösenkamp, Christoph, additional, Gesierich, Wolfgang, additional, Reichenberger, Frank, additional, Niehaus, Christa, additional, Herth, Felix, additional, Eberhardt, Ralf, additional, Gompelmann, Daniela, additional, Rump, Brigitte, additional, Darwiche, Kaid, additional, Eisenmann, Stephan, additional, Kaiser, Ulrike, additional, Schwarz, Birte, additional, Sampel, Ulrike, additional, Schumann, Christian, additional, Kaiser, Robert, additional, Schumann-Stoiber, Kathryn, additional, Skowasch, Dirk, additional, Ring, Sabine, additional, Briault, Amandine, additional, Arbib, Francois, additional, Jondot, Marie, additional, Perez, Thierry, additional, Fournier, Clement, additional, Matran, Regis, additional, Catto, Michele, additional, Bautin, Nathalie, additional, De Broucker, Virginie, additional, Willemin, Marie, additional, Prevotat, Anne, additional, Wemeau, Ludivine, additional, Gicquello, Alice, additional, Foulon, Morgane, additional, Camara, Hasna, additional, Deslee, Gaetan, additional, Vallerand, Herve, additional, Dury, Sandra, additional, Gras, Delphine, additional, Bonnaire-Verdier, Margaux, additional, Kessler, Romain, additional, Hirschi, Sandrine, additional, Porzio, Michele, additional, Degot, Tristan, additional, Canuet, Mathieu, additional, Schuller, Armelle, additional, Stauder, Julien, additional, Azouaou, Sahra Ali, additional, Marceau, Armelle, additional, Mal, Hervé, additional, Costa, Yolande, additional, Shah, Pallav L., additional, Garner, Justin, additional, Srikanthan, Karthi, additional, Caneja, Cielito, additional, Thornton, John, additional, Hacken, Nick Ten, additional, Hartman, Jorine, additional, Klooster, Karin, additional, Augustijn, Sonja, additional, Bonta, Peter, additional, Annema, Jouke, additional, van de Pol, Marianne, additional, and Goorsenberg, Annika, additional

Published
2023
Full Text
View/download PDF

29. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial

Author

Herth, Felix J F, Valipour, Arschang, Shah, Pallav L, Eberhardt, Ralf, Grah, Christian, Egan, Jim, Ficker, Joachim H, Wagner, Manfred, Witt, Christian, Liebers, Uta, Hopkins, Peter, Gesierich, Wolfgang, Phillips, Martin, Stanzel, Franz, McNulty, William H, Petermann, Christoph, Snell, Greg, and Gompelmann, Daniela

Published
2016
Full Text
View/download PDF

30. Additional file 2 of The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry

Author

Meischl, Tobias, Schmid-Scherzer, Karin, Vafai-Tabrizi, Florian, Wurzinger, Gert, Traunmüller-Wurm, Eva, Kutics, Kristina, Rauter, Markus, Grabcanovic-Musija, Fikreta, Müller, Simona, Kaufmann, Norbert, Löffler-Ragg, Judith, Valipour, Arschang, and Funk, Georg-Christian

Abstract

Additional file 2: Table S2. Phenotypes of the total population of the registry.

Published
2023
Full Text
View/download PDF

31. Additional file 1 of The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry

Author

Meischl, Tobias, Schmid-Scherzer, Karin, Vafai-Tabrizi, Florian, Wurzinger, Gert, Traunmüller-Wurm, Eva, Kutics, Kristina, Rauter, Markus, Grabcanovic-Musija, Fikreta, Müller, Simona, Kaufmann, Norbert, Löffler-Ragg, Judith, Valipour, Arschang, and Funk, Georg-Christian

Abstract

Additional file 1: Table S1. Baseline patient characteristics of the total population of the registry (n = 373).

Published
2023
Full Text
View/download PDF

32. Additional file 4 of The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry

Author

Meischl, Tobias, Schmid-Scherzer, Karin, Vafai-Tabrizi, Florian, Wurzinger, Gert, Traunmüller-Wurm, Eva, Kutics, Kristina, Rauter, Markus, Grabcanovic-Musija, Fikreta, Müller, Simona, Kaufmann, Norbert, Löffler-Ragg, Judith, Valipour, Arschang, and Funk, Georg-Christian

Abstract

Additional file 4: Table S4. Multivariable analysis of transplant-free survival (TS) by Cox regression (n = 229).

Published
2023
Full Text
View/download PDF

37. Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study

Author

Illini, Oliver, primary, Fabikan, Hannah, additional, Hochmair, Maximilian Johannes, additional, Weinlinger, Christoph, additional, Krenbek, Dagmar, additional, Brcic, Luka, additional, Setinek, Ulrike, additional, Terbuch, Angelika, additional, Absenger, Gudrun, additional, Konjić, Selma, additional, and Valipour, Arschang, additional

Published
2022
Full Text
View/download PDF

40. Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients

Author

Holzknecht, Arnulf, primary, Illini, Oliver, additional, Hochmair, Maximilian J., additional, Krenbek, Dagmar, additional, Setinek, Ulrike, additional, Huemer, Florian, additional, Bitterlich, Erwin, additional, Kaindl, Christoph, additional, Getman, Vladyslav, additional, Akan, Ahmet, additional, Weber, Michael, additional, Leobacher, Gunther, additional, Valipour, Arschang, additional, Mueller, Michael R., additional, and Watzka, Stefan B., additional

Published
2022
Full Text
View/download PDF

41. sj-docx-1-tam-10.1177_17588359221103206 – Supplemental material for Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Author

Illini, Oliver, Fabikan, Hannah, Swalduz, Aurélie, Vikström, Anders, Krenbek, Dagmar, Schumacher, Michael, Dudnik, Elizabeth, Studnicka, Michael, Öhman, Ronny, Wurm, Robert, Wannesson, Luciano, Peled, Nir, Kian, Waleed, Bar, Jair, Daher, Sameh, Addeo, Alfredo, Rotem, Ofer, Pall, Georg, Zer, Alona, Saad, Akram, Cufer, Tanja, Sorotsky, Hadas Gantz, Hashemi, Sayed M. S., Mohorcic, Katja, Stoff, Ronen, Rovitsky, Yulia, Keren-Rosenberg, Shoshana, Winder, Thomas, Weinlinger, Christoph, Valipour, Arschang, and Hochmair, Maximilian J.

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221103206 for Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program by Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour and Maximilian J. Hochmair in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

42. Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Author

Conway, Francesca, Tonkin, James, Valipour, Arschang, Pison, Christophe, Schumann, Christian, Bonta, Peter I., Kessler, Romain, Gesierich, Wolfgang, Darwiche, Kaid, Lamprecht, Bernd, Skowasch, Dirk, Johnson, Philip J., Slebos, Dirk-Jan, Shah, Pallav L., Groningen Research Institute for Asthma and COPD (GRIAC), Pulmonary medicine, Pulmonology, ACS - Pulmonary hypertension & thrombosis, and AII - Inflammatory diseases

Subjects
Male, Pulmonary and Respiratory Medicine, Emphysema, Cross-Over Studies, Interventional pulmonology, Chronic obstructive pulmonary disease, Medizin, Middle Aged, Denervation, Pulmonary Disease, Chronic Obstructive, Bronchoscopy, Quality of Life, Humans, Female, Pulmonary medicine, Lung, Aged
Abstract

Background: Targeted Lung Denervation (TLD) is a potential new therapy for COPD. Radiofrequency energy is bronchoscopically delivered to the airways to disrupt pulmonary parasympathetic nerves, to reduce bronchoconstriction, mucus hypersecretion, and bronchial hyperreactivity. Objectives: This work assesses the effect of TLD on COPD exacerbations (AECOPD) in crossover subjects in the AIRFLOW-2 trial. Method: The AIRFLOW-2 trial is a multicentre, randomized, double-blind, sham-controlled crossover trial of TLD in COPD. Patients with symptomatic COPD on optimal medical therapy with an FEV1 of 30–60% predicted received either TLD or sham bronchoscopy in a 1:1 randomization. Those in the sham arm had the opportunity to cross into the treatment arm after 12 months. The primary end point was rate of respiratory adverse events. Secondary end points included adverse events, changes in lung function and health-related quality of life and symptom scores. Results: Twenty patients were treated with TLD in the crossover phase and were subsequently followed up for 12 months (50% female, mean age 64.1 ± 6.9 years). After TLD, there was a trend towards a reduction in time to first AECOPD (hazard ratio 0.65, p = 0.28, not statistically significant) in comparison to sham follow-up period. There was also a reduction in time to first severe AECOPD in the crossover period (hazard ratio 0.38, p = 0.227, not statistically significant). Symptom scores and lung function showed stability. Conclusions: AIRFLOW-2 crossover data support that of the randomization phase, showing trends towards reduction in COPD exacerbations with TLD.

Published
2022

43. Recommendations for COPD management in Central and Eastern Europe

Author

Valipour, Arschang, primary, Aisanov, Zaurbek, additional, Avdeev, Sergey, additional, Koblizek, Vladimir, additional, Kocan, Ivan, additional, Kopitovic, Ivan, additional, Lupkovics, Gergely, additional, Man, Milena, additional, Bukovskis, Maris, additional, Tudoric, Neven, additional, Vukoja, Marija, additional, Naumnik, Wojciech, additional, and Yanev, Nikolay, additional

Published
2022
Full Text
View/download PDF

46. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Author

Illini, Oliver, primary, Fabikan, Hannah, additional, Swalduz, Aurélie, additional, Vikström, Anders, additional, Krenbek, Dagmar, additional, Schumacher, Michael, additional, Dudnik, Elizabeth, additional, Studnicka, Michael, additional, Öhman, Ronny, additional, Wurm, Robert, additional, Wannesson, Luciano, additional, Peled, Nir, additional, Kian, Waleed, additional, Bar, Jair, additional, Daher, Sameh, additional, Addeo, Alfredo, additional, Rotem, Ofer, additional, Pall, Georg, additional, Zer, Alona, additional, Saad, Akram, additional, Cufer, Tanja, additional, Sorotsky, Hadas Gantz, additional, Hashemi, Sayed M. S., additional, Mohorcic, Katja, additional, Stoff, Ronen, additional, Rovitsky, Yulia, additional, Keren-Rosenberg, Shoshana, additional, Winder, Thomas, additional, Weinlinger, Christoph, additional, Valipour, Arschang, additional, and Hochmair, Maximilian J., additional

Published
2022
Full Text
View/download PDF

47. Bronchoscopic Lung Volume Reduction Coil Treatment for Severe Emphysema: A Systematic Review and Meta-Analysis of Individual Participant Data

Author

Roodenburg, Sharyn A., primary, Hartman, Jorine E., additional, Deslée, Gaëtan, additional, Herth, Felix J.F., additional, Klooster, Karin, additional, Sciurba, Frank C., additional, Shah, Pallav L., additional, Valipour, Arschang, additional, Zoumot, Zaid, additional, and Slebos, Dirk-Jan, additional

Published
2022
Full Text
View/download PDF

49. Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients

Author

Valipour, Arschang, Shah, Pallav L, Pison, Christophe, Ninane, Vincent, Janssens, Wim, Perez, Thierry, Kessler, Romain, Deslee, Gaetan, Garner, Justin, Abele, Christine, Hartman, Jorine E, Slebos, Dirk-Jan, Chen, A, Gorden, J, Issa, Z, McDonald, G, Pulling, C, Aalbers, R, Ferrera, D, Leh, L, Firlinger, Irene, Kothakuzhakal, Kiran, Duller, Marina, Muylle, Inge, Rummens, Peter, De Cock, Frederique, Dooms, Christophe, DeBent, Kristien, Briault, Amandine, Arbib, Francois, Jondot, Marie, Ferretti, Gilbert, Fournier, Clement, Matran, Regis, Catto, Michele, Bautin, Nathalie, De Broucker, Virginie, Willemin, Marie, Prevotat, Anne, Wemeau, Ludivine, Gicquello, Alice, Foulon, Morgane, Camara, Hasna, Vallerand, Herve, Dury, Sandra, Gras, Delphine, Bonnaire-Verdier, Margaux, Hirschi, Sandrine, Porzio, Michele, Degot, Tristan, Canuet, Mathieu, Schuller, Armelle, Stauder, Julien, Azouaou, Sahra Ali, Srikanthan, Karthi, Caneja, Cielito, Thornton, John, Ten Hacken, Nick, Hartman, Jorine, Augustijn, Sonja, Klooster, Karin, Groningen Research Institute for Asthma and COPD (GRIAC), Department of Respiratory and Critical Care Medicine, Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology, Otto-Wagner-Spital, Vienna, Royal Brompton and Harefield NHS Trust, Chelsea and Westminster Hospital, and Imperial College, London, Centre Hospitalier Universitaire [Grenoble] (CHU), Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), CHU Saint-Pierre, Université libre de Bruxelles, Bruxelles, Department of Respiratory Diseases, KU Leuven, University Hospitals Leuven, Leuven, Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Service de Pneumologie, Nouvel Hôpital Civil, Université de Strasbourg, Strasbourg, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), University Medical Center Groningen [Groningen] (UMCG), Imperial College London, Université libre de Bruxelles (ULB), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Pulmonary and Respiratory Medicine, Male, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Quality of life, Randomized controlled trial, law, Bronchoscopy, Parasympathectomy, medicine, Clinical endpoint, Humans, Interventional Pulmonology, 030212 general & internal medicine, Dosing, Adverse effect, Lung, Aged, COPD, business.industry, Radiofrequency ablation, Middle Aged, medicine.disease, Acetylcholine, 3. Good health, medicine.anatomical_structure, 030228 respiratory system, Anesthesia, Lung disease obstructive, Female, Pneumologie, Airway, business
Abstract

Rationale: Targeted lung denervation (TLD) is a novel bronchoscopic treatment for the disruption of parasympathetic innervation of the lungs. Objectives: To assess safety, feasibility, and dosing of TLD in patients with moderate to severe COPD using a novel device design. Methods: Thirty patients with COPD (forced expiratory volume in 1 s 30-60%) were 1:1 randomized in a double-blinded fashion to receive TLD with either 29 or 32 W. Primary endpoint was the rate of TLD-associated adverse airway effects that required treatment through 3 months. Assessments of lung function, quality of life, dyspnea, and exercise capacity were performed at baseline and 1-year follow-up. An additional 16 patients were enrolled in an open-label confirmation phase study to confirm safety improvements after procedural enhancements following gastrointestinal adverse events during the randomized part of the trial. Results: Procedural success, defined as device success without an in-hospital serious adverse event, was 96.7% (29/30). The rate of TLD-associated adverse airway effects requiring intervention was 3/15 in the 32 W versus 1/15 in the 29 W group, p = 0.6. Five patients early in the randomized phase experienced serious gastric events. The study was stopped and procedural changes made that reduced both gastrointestinal and airway events in the subsequent phase of the randomized trial and follow-up confirmation study. Improvements in lung function and quality of life were observed compared to baseline values for both doses but were not statistically different. Conclusions: The results demonstrate acceptable safety and feasibility of TLD in patients with COPD, with improvements in adverse event rates after procedural enhancements., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results